| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8647291 | Multiple Sclerosis and Related Disorders | 2018 | 8 Pages |
Abstract
pwPMS with detectable disease activity (MRI, elevated NfL) should be considered for DMT. NfL appears to be a sensitive index of treatment effect in pwPMS, and may be a useful outcome in clinical trials targeting this patient group. Over and above its licensed indication (relapsing MS), cladribine may be an effective treatment option for pwPMS.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
O. Yildiz, Z. Mao, A. Adams, N. Dubuisson, K. Allen-Philbey, G. Giovannoni, A. Malaspina, D. Baker, S. Gnanapavan, K. Schmierer,